Proactive Investors - Run By Investors For Investors

Cosmos Holdings names agribusiness exec Vassos Efthymiadis to advisory board

Efthymiadis is president of the Hellenic Crop Protection Association
bottle of pills
Cosmos Holdings specializes in acquiring, developing, and commercializing medicines

Cosmos Holdings Inc (OTCQB:COSM) has added executive Vassos Efthymiadis to its advisory board.

Efthymiadis boasts considerable experience in the agribusiness sector and joins the board of the international pharmaceutical company, having served as Managing Director of K&N Efthymiadis SA and the vice-president of the Redestos Agrotechnology Group, two agribusiness companies in Greece.

READ: Cosmos Holdings pays off all its convertible debt

Efthymiadis is also president of the Hellenic Crop Protection Association and a board member of the Hellenic Association of Chemical Industries.

Grigorios Siokas, CEO of Cosmos, is bullish on Efthymiadis’s appointment, citing his expertise in European exports. “His experience with exports to various countries of Southeastern Europe will provide valuable insight as we expand. We are excited to welcome him to the Cosmos team,” Siokas said in a statement.

READ: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

Efthymiadis is keen to start at Cosmos. “Coming from a not so dissimilar business segment, I feel confident my experience can contribute to the vision Greg and his great team are shaping regarding the future of the company and the best way to ensure its long-term growth,” he said in a statement.

Cosmos Holdings is a pharmaceutical wholesaler with offices and warehouses in Thessaloniki and Athens, Greece as well as the UK.

Cosmos shares traded 1.7% higher to hit $3.50 on Wednesday morning.

Contact Ellen Kelleher at [email protected]

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Related Articles

A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use